Comparison of gallium-67 citrate and technetium-99m tetrofosmin scan to detect Hodgkin’s disease
Tóm tắt
Objective: The purpose of this study was to compare the usefulness of gallium-67 citrate (67Ga) and technetium-99m tetrofosmin (Tc-TF) scan to detect Hodgkin’s disease (HD).Methods: In this study, 24 patients with HD underwent67Ga and Tc-TF scan before receiving any therapy.Results:67Ga scan could detect HD in all 24 (100%) patients. Tc-TF scan could detect HD in 22/24 (91.6%) patients, but it was false-negative in one case of infradiaphragmatic HD and in another, case with chemotherapy resistance. There was no significant difference in detection sensitivity between67Ga and Tc-TF scan.Conclusions: We conclude that Tc-TF scan can not replace conventional67Ga scan to detect HD.
Tài liệu tham khảo
Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?Eur J Nucl Med 2000; 27: 1564–1578.
Hayes R. The medical use of gallium radionuclides: a brief history with some comments.Semin Nucl Med 1978; 8: 183–191.
Front D, Bar-Shalom P, Epelbaum R, et al. Early detection of lymphoma recurrence with gallium-67 scintigraphy.J. Nucl Med 1992; 34: 2101–2104.
Front D, Ben-Haim S, Israel O, Epelbaum R, Haim N, Even-Sapir E, et al. Lymphoma: predictive value of Ga-67 scintigraphy after treatment.Radiology 1992; 182: 359–363.
Front D, Israel O. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients.Semin Nucl Med 1995; 25: 60–71.
Turner D, Fordham E, Ali A, Slayton R. Gallium-67 imaging in the management of Hodgkin’s disease and other malignant lymphomas.Semin Nucl Med 1978; 8: 205–218.
Aigner RM, Fueger GF, Zinke W, Sill H. Tc-99m-tetrofosmin scintigraphy in Hodgkin’s disease.Nucl Med Commun 1997; 18: 252–257.
Lee JK, Tsai SC, Ho YJ, Changlai, SP, Kao CH. Technetium-99m tetrofosmin scintigraphy, for detecting malignant lymphoma.Anticancer Res 2001; 21: 1509–1514.
Jaffe ES. Histopathology of the non-Hodgkin’s lymphomas and Hodgkin’s disease. In:The Lymphomas, 1st edition, Canellos GP, Lister TA, Sklar JL (eds). Philadelphia; W.B. Saunders Company, 1998; 77–106.
Yang CC, Sun SS, Lin CC, Kao CH, Lee CC. Comparison of technetium-99m tetrofosmin and gallium-67 citrate scintigraphy for detecting malignant lymphoma.Anticancer Res 2001; 21: 3695–3698.
Higley B, Smith FW, Smith T, Gemmell HG, Das Gupta P, Gvozdanovic DV, et al. Technetium-99m-1,2(bis(2-ethoxyethyl)phosphino)ethane: Human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent.J Nucl Med 1993; 34: 30–38.
Kelly JD, Forster AM, Higley, B, Archer CM, Booker FS, Canning LR, et al. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging.J Nucl Med 1993; 34: 222–227.
Piwnica Worms D, Holman LB. Noncardiac application of hexakis (alkyl-isonitrile) technetium-99m complexes.J Nucl Med 1990; 31: 1166–1167.
Liang JA, Shiau YC, Yang SN, Lin FJ, Lin CC, Kao A, et al. Using technetium-99m-tetrofosmin scan to predict chemotherapy response of malignant lymphomas, compared with P-glycoprotein and multidrug resistance related protein expression.Oncol Rep 2002; 9: 307–312.
Shiau YC, Tsai SC, Wang JJ, Ho YJ, Ho ST, Kao CH. Predicting chemotherapy response and comparing with Pglycoprotein expression using technetium-99m tetrofosmin scan in untreated malignant lymphomas.Cancer Lett 2001; 170: 139–146.
Sun SS, Tsai SC, Wang JJ, Ho YJ, Ho ST, Kao CH. Technetium-99m-tetrofosmin scintigraphy in the prediction of chemotherapy response of untreated malignant lymphomas and comparison with other prognostic factors.Anticancer Res 2001; 21: 685–688.